Invivyd, Inc.

IVVD Healthcare Biotechnology

Invivyd, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $53.4 million, up 110.5% from fiscal 2024. In the quarter to June 2026, revenue grew 21.2%, EPS fell 16.7% and free cash flow fell 226.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

0.67 0.06 +9.84%
Market cap
$190.4M
P/E
0.0×
Fwd P/E
−2.5×
Dividend yield
—
F-score
n/a
Altman Z
2.85
Beneish M
−1.63
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(67.94%) (33.96%) (60.34%) (95.89%)
ROA
(39.76%) (25.83%) (44.92%) (69.69%)
ROIC
(480.14%) (233.82%) (270.46%) (334.92%)
Return on Tangible Assets
(89.97%) (24.45%) (44.36%) (70.03%)
Average Days of Receivables
71.86 95.09 76.10 70.18
Free Cash Flow per Share
(0.47) (0.34) (0.26) (0.34)
Free Cash Flow
(80.44) (58.29) (79.45) (109.66)
Other line items

Show all line items

Columns are period end dates